Skip to content
Dual GIP/GLP-1 Receptor Agonist / Incretin Mimetic

Tirzepatide (Mounjaro / Zepbound)

A dual incretin agonist that activates both GIP and GLP-1 receptors, producing the largest weight loss of any approved pharmacotherapy to date. SURMOUNT-1 demonstrated up to 22.5% body-weight reduction at 72 weeks on the 15mg dose — outperforming semaglutide head-to-head. The added GIP component improves insulin sensitivity and may partially offset the muscle loss seen with GLP-1 monotherapy.

fat-lossmetabolic-healthcardiovascular-protectionlongevity
Tier B— Generally safe — moderate evidence
Evidence gradeA — Multiple RCTs / Meta-analysis
BH

Editorially reviewed by

BiohackingHub Research Team

Editorial Team · Last updated: November 18, 2026

Stacking Interactions

How Tirzepatide (Mounjaro / Zepbound) interacts with other compounds

+
CreatineSynergisticmoderate evidence

Creatine supports strength and lean-mass retention during the rapid weight loss tirzepatide drives — a cornerstone of muscle-preservation protocols.

=
BerberineNeutralweak evidence

Sometimes suggested as a bridge after stopping tirzepatide. No study has tested it for keeping weight off after a GLP-1 drug.

!
SemaglutideCautionstrong evidence

Both are incretin agonists — do not combine. Tirzepatide is typically used instead of, not alongside, semaglutide.

+
NMNSynergisticweak evidence

Pairs in longevity-oriented metabolic protocols; reduced insulin signalling from tirzepatide complements NAD+-driven mitochondrial support.

Protocols using Tirzepatide (Mounjaro / Zepbound)

Evidence-graded stacks that include this compound

Safety Profile — Tier B

Generally safe — moderate evidence

Contraindications

  • ●Personal or family history of medullary thyroid carcinoma (MTC)
  • ●Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
  • ●History of pancreatitis
  • ●Pregnancy and breastfeeding
  • ●Severe gastrointestinal disease or gastroparesis

Side Effects

  • ●Nausea — common, especially during titration (dose-dependent)
  • ●Diarrhoea and vomiting
  • ●Constipation
  • ●Reduced appetite (intended effect)
  • ●Fatigue and lean-mass loss during rapid weight loss
  • ●Rare: pancreatitis, gallbladder disease

Drug Interactions

Insulin and sulfonylureas — additive hypoglycaemia risk; doses often reducedOral medications — delayed gastric emptying can alter absorption timing